Relationship between HLA-B*5801 Gene Polymorphism and Allopurinol-induced ADR in Han Population of Hainan Province
10.6039/j.issn.1001-0408.2018.09.25
- VernacularTitle:海南省汉族人群HLA-B*5801基因多态性与别嘌醇所致不良反应的相关性研究
- Author:
Xiong YUN
1
;
Danna WU
;
Fangxuan HAN
;
Chunxin HUANG
;
Wenxing PENG
Author Information
1. 中南大学湘雅二医院药学部
- Keywords:
HLA-B*5801;
Allopurinol;
Gene polymorphism;
ADR;
Hainan province;
Han population
- From:
China Pharmacy
2018;29(9):1256-1259
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the relationship between HLA-B*5801 gene polymorphism and allopurinol-induced ADR in the Han population of Hainan Province. METHODS:The in-situ hybridization fluorescence staining analysis technique was used to detect HLA-B*5801 allele of 149 inpatients receiving allopurinol in Hainan Provincial People's Hospital during Sept. 2015-Sept. 2017.They were divided into tolerance group and ADR group according to ADR.Woolf's formula was used to calculate OR. The correlation of HLA-B*5801 allele with the occurrence of allopurinol-induced ADR was analyzed. RESULTS:Of 149 patients,there were 133 cases in tolerance group,among which 17.29%(23/133)carried HLA-B*5801 allele.There were 16 cases in ADR group,among which 93.75%(15/16)carried HLA-B*5801 allele. Among 16 ADR patients,13 patients suffered from lesion of skin and its appendents;1 patient suffered from systemic damage;1 patient suffered from gastrointestinal systemic damage;1 patient suffered from central and peripheral nervous system damage. The risk of ADR in patients with HLA-B*5801 allele was significantly higher than patients without HLA-B*5801 allele(OR:71.74,95%CI:9.02-570.55,P<0.000). The lesion of skin and its appendents was strongly associated with HLA-B*5801 allele(OR:57.39,95%CI:7.11-463.50,P<0.000). CONCLUSIONS:HLA-B*5801 allele is strongly associated with allopurinol-induced ADR. It is suggested that HLA-B*5801 allele of Han patients should be detected before taking allopurinol,which helps to reduce the incidence of allopurinol-induced ADR.
